Resolvin El, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets

Maria Dona, Gabrielle Fredman, Jan M. Schwab, Nan Chiang, Makoto Arita, Ahmad Goodarzi, Guiying Cheng, Ulrich H. Von Andrian, Charles N. Serhan

Research output: Contribution to journalArticle

147 Citations (Scopus)

Abstract

Resolvin E1 (RvE1) is an omega-3 eicosapentaenoic acid (EPA)-derived lipid mediator generated during resolution of inflammation and in human vasculature via leukocyte-endothelial cell interactions. RvE1 possesses anti-inflammatory and proresolving actions. Here, we report that RvE1 in human whole blood rapidly regulates leukocyte expression of adhesion molecules. RvE1 in the 10- to 100-nM range stimulated L-selectin shedding, while reducing CD18 expression in both neutrophils and monocytes. When added to whole blood, RvE1 did not stimulate reactive oxygen species by either neutrophils or monocytes, nor did it directly stimulate cytokine/chemokine production in heparinized blood. Intravital microscopy (IVM) demonstrated that RvE1 rapidly reduced leukocyte rolling (∼ 40%) in venules of mice. In human platelet-rich plasma (PRP), RvE1 selectively blocked both ADP-stimulated and thromboxane receptor agonist U46619-stimulated platelet aggregation in a concentrationdependent manner. In contrast, δ6, 14-trans-RvE1 isomer was inactive. RvE1 did not block collagen-stimulated aggregation, and regulation of ADP-induced platelet aggregation was not further enhanced with aspirin treatment. These results indicate RvE1 is a potent modulator of leukocytes as well as selective platelet responses in blood and PRP, respectively. Moreover, the results demonstrate novel agonist-specific antiplatelet actions of RvE1 that are potent and may underlie some of the beneficial actions of EPA in humans.

Original languageEnglish
Pages (from-to)848-855
Number of pages8
JournalBlood
Volume112
Issue number3
DOIs
Publication statusPublished - 2008 Aug 1
Externally publishedYes

Fingerprint

Eicosapentaenoic Acid
Platelets
Leukocytes
Blood
Blood Platelets
Platelet-Rich Plasma
Agglomeration
Platelet Aggregation
Adenosine Diphosphate
Monocytes
Neutrophils
5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid
Leukocyte Rolling
Thromboxane Receptors
Purinergic P2 Receptors
Plasmas
L-Selectin
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
Venules
Endothelial cells

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Dona, M., Fredman, G., Schwab, J. M., Chiang, N., Arita, M., Goodarzi, A., ... Serhan, C. N. (2008). Resolvin El, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets. Blood, 112(3), 848-855. https://doi.org/10.1182/blood-2007-11-122598

Resolvin El, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets. / Dona, Maria; Fredman, Gabrielle; Schwab, Jan M.; Chiang, Nan; Arita, Makoto; Goodarzi, Ahmad; Cheng, Guiying; Von Andrian, Ulrich H.; Serhan, Charles N.

In: Blood, Vol. 112, No. 3, 01.08.2008, p. 848-855.

Research output: Contribution to journalArticle

Dona, M, Fredman, G, Schwab, JM, Chiang, N, Arita, M, Goodarzi, A, Cheng, G, Von Andrian, UH & Serhan, CN 2008, 'Resolvin El, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets', Blood, vol. 112, no. 3, pp. 848-855. https://doi.org/10.1182/blood-2007-11-122598
Dona, Maria ; Fredman, Gabrielle ; Schwab, Jan M. ; Chiang, Nan ; Arita, Makoto ; Goodarzi, Ahmad ; Cheng, Guiying ; Von Andrian, Ulrich H. ; Serhan, Charles N. / Resolvin El, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets. In: Blood. 2008 ; Vol. 112, No. 3. pp. 848-855.
@article{b0d51e30a6e64be88baf746991eede3b,
title = "Resolvin El, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets",
abstract = "Resolvin E1 (RvE1) is an omega-3 eicosapentaenoic acid (EPA)-derived lipid mediator generated during resolution of inflammation and in human vasculature via leukocyte-endothelial cell interactions. RvE1 possesses anti-inflammatory and proresolving actions. Here, we report that RvE1 in human whole blood rapidly regulates leukocyte expression of adhesion molecules. RvE1 in the 10- to 100-nM range stimulated L-selectin shedding, while reducing CD18 expression in both neutrophils and monocytes. When added to whole blood, RvE1 did not stimulate reactive oxygen species by either neutrophils or monocytes, nor did it directly stimulate cytokine/chemokine production in heparinized blood. Intravital microscopy (IVM) demonstrated that RvE1 rapidly reduced leukocyte rolling (∼ 40{\%}) in venules of mice. In human platelet-rich plasma (PRP), RvE1 selectively blocked both ADP-stimulated and thromboxane receptor agonist U46619-stimulated platelet aggregation in a concentrationdependent manner. In contrast, δ6, 14-trans-RvE1 isomer was inactive. RvE1 did not block collagen-stimulated aggregation, and regulation of ADP-induced platelet aggregation was not further enhanced with aspirin treatment. These results indicate RvE1 is a potent modulator of leukocytes as well as selective platelet responses in blood and PRP, respectively. Moreover, the results demonstrate novel agonist-specific antiplatelet actions of RvE1 that are potent and may underlie some of the beneficial actions of EPA in humans.",
author = "Maria Dona and Gabrielle Fredman and Schwab, {Jan M.} and Nan Chiang and Makoto Arita and Ahmad Goodarzi and Guiying Cheng and {Von Andrian}, {Ulrich H.} and Serhan, {Charles N.}",
year = "2008",
month = "8",
day = "1",
doi = "10.1182/blood-2007-11-122598",
language = "English",
volume = "112",
pages = "848--855",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - Resolvin El, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets

AU - Dona, Maria

AU - Fredman, Gabrielle

AU - Schwab, Jan M.

AU - Chiang, Nan

AU - Arita, Makoto

AU - Goodarzi, Ahmad

AU - Cheng, Guiying

AU - Von Andrian, Ulrich H.

AU - Serhan, Charles N.

PY - 2008/8/1

Y1 - 2008/8/1

N2 - Resolvin E1 (RvE1) is an omega-3 eicosapentaenoic acid (EPA)-derived lipid mediator generated during resolution of inflammation and in human vasculature via leukocyte-endothelial cell interactions. RvE1 possesses anti-inflammatory and proresolving actions. Here, we report that RvE1 in human whole blood rapidly regulates leukocyte expression of adhesion molecules. RvE1 in the 10- to 100-nM range stimulated L-selectin shedding, while reducing CD18 expression in both neutrophils and monocytes. When added to whole blood, RvE1 did not stimulate reactive oxygen species by either neutrophils or monocytes, nor did it directly stimulate cytokine/chemokine production in heparinized blood. Intravital microscopy (IVM) demonstrated that RvE1 rapidly reduced leukocyte rolling (∼ 40%) in venules of mice. In human platelet-rich plasma (PRP), RvE1 selectively blocked both ADP-stimulated and thromboxane receptor agonist U46619-stimulated platelet aggregation in a concentrationdependent manner. In contrast, δ6, 14-trans-RvE1 isomer was inactive. RvE1 did not block collagen-stimulated aggregation, and regulation of ADP-induced platelet aggregation was not further enhanced with aspirin treatment. These results indicate RvE1 is a potent modulator of leukocytes as well as selective platelet responses in blood and PRP, respectively. Moreover, the results demonstrate novel agonist-specific antiplatelet actions of RvE1 that are potent and may underlie some of the beneficial actions of EPA in humans.

AB - Resolvin E1 (RvE1) is an omega-3 eicosapentaenoic acid (EPA)-derived lipid mediator generated during resolution of inflammation and in human vasculature via leukocyte-endothelial cell interactions. RvE1 possesses anti-inflammatory and proresolving actions. Here, we report that RvE1 in human whole blood rapidly regulates leukocyte expression of adhesion molecules. RvE1 in the 10- to 100-nM range stimulated L-selectin shedding, while reducing CD18 expression in both neutrophils and monocytes. When added to whole blood, RvE1 did not stimulate reactive oxygen species by either neutrophils or monocytes, nor did it directly stimulate cytokine/chemokine production in heparinized blood. Intravital microscopy (IVM) demonstrated that RvE1 rapidly reduced leukocyte rolling (∼ 40%) in venules of mice. In human platelet-rich plasma (PRP), RvE1 selectively blocked both ADP-stimulated and thromboxane receptor agonist U46619-stimulated platelet aggregation in a concentrationdependent manner. In contrast, δ6, 14-trans-RvE1 isomer was inactive. RvE1 did not block collagen-stimulated aggregation, and regulation of ADP-induced platelet aggregation was not further enhanced with aspirin treatment. These results indicate RvE1 is a potent modulator of leukocytes as well as selective platelet responses in blood and PRP, respectively. Moreover, the results demonstrate novel agonist-specific antiplatelet actions of RvE1 that are potent and may underlie some of the beneficial actions of EPA in humans.

UR - http://www.scopus.com/inward/record.url?scp=50949126869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50949126869&partnerID=8YFLogxK

U2 - 10.1182/blood-2007-11-122598

DO - 10.1182/blood-2007-11-122598

M3 - Article

C2 - 18480426

AN - SCOPUS:50949126869

VL - 112

SP - 848

EP - 855

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -